» Articles » PMID: 23078073

Moderate Influenza Vaccine Effectiveness with Variable Effectiveness by Match Between Circulating and Vaccine Strains in Australian Adults Aged 20-64 Years, 2007-2011

Overview
Publisher Wiley
Specialty Microbiology
Date 2012 Oct 20
PMID 23078073
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Influenza vaccines are licensed annually based on immunogenicity studies. We used five sequential years of data to estimate influenza vaccine effectiveness (VE), the critical outcome in the field.

Methods: Between 2007 and 2011, we performed annual prospective test-negative design case-control studies among adults aged 20-64 years recruited from sentinel general practices in the Australian state of Victoria. We used PCR-confirmed influenza as the endpoint to estimate influenza VE for all years. We compared annual VE estimates with the match between circulating and vaccine strains, determined by haemagglutination inhibition assays.

Results: The adjusted VE estimate for all years (excluding 2009) was 62% (95% CI 43, 75). By type and subtype, the point estimates of VE by year ranged between 31% for seasonal influenza A(H1N1) and 88% for influenza A(H1N1)pdm09. In 2007, when circulating strains were assessed as incompletely matched, the point estimate of the adjusted VE against all influenza was 58%. The point estimate was 59% in 2011 when all strains were assessed as well matched.

Conclusion: Trivalent inactivated vaccines provided moderate protection against laboratory-confirmed influenza in adults of working age, although VE estimates were sensitive to the model used. VE estimates correlated poorly with circulating strain match, as assessed by haemagglutination inhibition assays, suggesting a need for VE studies that incorporate antigenic characterization data.

Citing Articles

Estimated health and economic impact of using high-dose influenza vaccine on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia.

MacIntyre C, Kevin Yin J, Felter C, Menzies R, Thommes E, Largeron N Vaccine X. 2023; 15:100365.

PMID: 37609557 PMC: 10440578. DOI: 10.1016/j.jvacx.2023.100365.


Comparison of the Hemagglutination Inhibition Titers against Influenza Vaccine Strains in Japan from the 2017/2018 to 2021/2022 Seasons Using a Single Set of Serum Samples.

Otani N, Nakajima K, Ishikawa K, Ichiki K, Yoda Y, Ueda T Viruses. 2022; 14(7).

PMID: 35891435 PMC: 9323423. DOI: 10.3390/v14071455.


Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study.

Brazete C, Pinto M, Sa L, Aguiar A, Alves F, Duarte R Vaccines (Basel). 2022; 10(5).

PMID: 35632578 PMC: 9147572. DOI: 10.3390/vaccines10050822.


A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children.

Yildirim I, Kao C, Tippett A, Suntarattiwong P, Munye M, Yi J Clin Infect Dis. 2021; 73(10):1759-1767.

PMID: 34410341 PMC: 8599178. DOI: 10.1093/cid/ciab709.


Decline in Seasonal Influenza Vaccine Effectiveness With Vaccination Program Maturation: A Systematic Review and Meta-analysis.

Okoli G, Racovitan F, Abdulwahid T, Hyder S, Lansbury L, Righolt C Open Forum Infect Dis. 2021; 8(3):ofab069.

PMID: 33738320 PMC: 7953658. DOI: 10.1093/ofid/ofab069.


References
1.
Fielding J, Grant K, Tran T, Kelly H . Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Euro Surveill. 2012; 17(11). View

2.
Skowronski D, Janjua N, De Serres G, Winter A, Dickinson J, Gardy J . A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis. 2012; 55(3):332-42. DOI: 10.1093/cid/cis431. View

3.
Orenstein E, De Serres G, Haber M, Shay D, Bridges C, Gargiullo P . Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007; 36(3):623-31. DOI: 10.1093/ije/dym021. View

4.
Petrie J, Ohmit S, Johnson E, Cross R, Monto A . Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011; 203(9):1309-15. PMC: 3069734. DOI: 10.1093/infdis/jir015. View

5.
Kelly H, Barr I . Large trials confirm immunogenicity of H1N1 vaccines. Lancet. 2009; 375(9708):6-9. DOI: 10.1016/S0140-6736(09)62132-2. View